# Pyrroloylpyrrole derivatives, processes for their preparation and their use.

## Abstract
Compounds of formula I

## Claims
Claims 1. A compound of formula I EMI52.1 or a pharmaceutically acceptable salt or a pro drug thereof, wherein R1 and R2 are the same or different and are hydrogen, halogen or C14 alkyl R3 is hydrogen or C1 6 alkyl R4 is hydrogen or methyl and n is O or 1. 2. A compound according to claim 1 wherein the moiety of formula EMI52.2 is 4 chloropyrroloyl, 4 bromopyrroloyl, 4,5dichloropyrroloyl, 4,5 dibromopyrroloyl, 5 methyl pyrroloyl, 5 ethylpyrroloyl, 3,5 dimethylpyrroloyl, 3, 5 diethylpyrroloyl, 4, 5 dimethylpyrroloyl, or 4, 5 diethylpyrroloyl. 3. A compound according to claim 1 wherein R1 and R2 are both hydrogen. 4. A compound according to any one of the claims 1 to 3 wherein R3 is methyl. 5. A compound according to any one of the claims 1 to 4 wherein n is O. 6. A pro drug of a compound according to claim 1 wherein the CO2H group is replaced by an in vivo hydrolysable ester or amide group,a CHO or CH2OH group or wherein the CO2H group is replaced by a group of one of the sub formulae a j CH2 CO CH3 a CH2 CHOH CH3 b CH C OR5 CH3 c CHOH CO CH3 d CHOH CHOH CH3 e CH2 C OR5 CH2 f CH2 C OCOR5 CH2 g CH C OCOR5 CH3 h CH20C OR6 OR7 CH3 i CH2 CH OCOR8 CH3 j wherein R5 is C1 4 alkyl R6 and R7 are each C1 4 alkyl or together are CH2CH2 or CH2CH2CH2 and R8 is C14 alkyl optionally substituted by phenyl or optionally salified amino. 7. A compound according to claim 1 of formula VI EMI54.1 or a pharmaceutically acceptable salt thereof or a pro drug thereof of formula VIII , IX , X , XI or XII EMI54.2 EMI55.1 wherein the variables are as defined in claim 1. 8. 2 Carboxymethyl 1 methyl 5 1 methyl 2 pyrroloyl pyrrole or 2 e thoxycarbonylmethyl 1 ,4 dimethyl 5 1 methyl 2 pyrroloyl pyrrole. 9. A process for the preparation of a compound according to claim 1, or a pharmaceutically acceptable salt thereof characterised by either i the basic hydrolysis of a compound of the formula XXI EMI56.1 wherein R1, R2 R3 and R4 are as defined in claim 1 and L is CN or a group CO2R9 in which Rg is C14 alkyl and therafter if desired converting R3 when hydrogen in the resultant compound of the formula I to C1 6 alkyl and if desired acidifying the resulting salt to form a compound of formula I , or converting a salt to a pharmaceutically acceptable salt thereof, or to another pharmaceutically acceptable salt thereof or ii when R3 is C1 6 alkyl, the decarboxylation of a compound of the formula XXIII EMI56.2 wherein R10 is C1 4 alkyl wher n is O or h when n is 1 and therafter if desired salifying the resultant compound to give a pharmaceutically acceptable salt or converting a salt to a pharmaceutically acceptable salt. 10. A process for the preparation of a pro drug according to claim 6 characterised by, when theCOOH group is replaced by i an in vivo hydrolysable ester group esterifying a compound according to claim 1 or an active acylating derivative with the corresponding alcohol ii an in vivo hydrolysable amide group, reacting an active derivative of a compound according to clam 1 with ammonia or a corresponding amine iii an CHO group or CH2OH group reducing an acid halide of a compound according to claim 1 and thereafter if desired further reducing the resulting compound wherein C02H is replaced by CHO iv a group of sub formula a as defined in claim 6, oxidising a compound of the formula XXIX EMI57.1 or decarboxylating a compound of formula XXXI I EMI57.2 wherein the variables are as defined in claim 1 v a group of sub formula b as defined in claim 6, reducing a compound according to claim 1 wherein the CO2H group is replaced by a group of sub formula a vi a group of sub formula c as defined in claim 6 enol etherifying a compound according to claim 1 wherein the CO2H group is replaced by a group of sub formula a vii a group of sub formula d as defined in claim 6, oxidising a compound according to claim 1 wherein the CO2H group is replaced by a group of sub formula c viii a group of sub formula e as defined in claim 6, reducing a compound according to claim 1 wherein the CO2H group is replaced by a group of sub formula d viv a group of sub formula f , g , h , i or j as defined in claim 6, a process as described in Belgium Patent No. 866,587. 11. A pharmaceutical composition comprising a compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt or a pro drug thereof and a pharmaceutically acceptable carrier. 12. A compound according to any one of the claims 1 to 9 or a pharmaceutically acceptable salt or a pro drug thereof for use as in treating inflammatory and or painful conditions in mammals.

## Description
Pyrroloylpyrrole derivatives, processes for their preparation and their use The present invention relates to cyclic compounds having useful pharmacological activity, to processes for their preparation and to pharmaceutical compositions containing them. Tolmetin, a clinically used anti inflammatory and analgesic agent of the formula A EMI1.1 and related compound have been described in J. Pharmacol. Exptl Therap. 1973, 185, 127 138, U.S. Patent SpecificationNo. 3,752,826 and U.K. Patent Specification No. 1,195,628. It has now been found that certain other arylacetic acids possess good anti inflammatory and analgesic activity. Accordingly, the present invention provides compounds of the formula I EMI2.1 and pharmaceutically acceptable salts and pro drugs thereof, wherein R1 and R2 are the same or different and are hydrogen, halogen or C1 4 alkyl R3 is hydrogen or C16 alkyl R4 is hydrogen or methyl and n is O or 1. When used herein the term pro drug means a compound metabolised in vivo to a compound of the formula I or its salt. A. pro drug may be identified by administering the pro drug to a mammal such as a rat, mouse, dog, monkey or man and identifying the compound of the formula I or its salt, in for example blood or urine. One class of pro drugs of the compounds of the formula I consists of in vivo hydrolysable esters..Such esters may be simple alkyl esters such as the methyl, ethyl, propyl or butyl esters, simply substituted alkyl esters such as the methoxymethyl, 2 methoxyethyl, 2 hydroxyethyl or benzyl esters cr other esters conventionally used in the medical arts as pro drugs such as a C1 4 acyloxymethyl, are C1,Q acyloxyethyl, C1 4 alkoxycarbonyloxymethyl, , alkoxycarbonyloxy methyl, or phthalidyl. A further class of pro drugs for the compounds of the formula I consists of in vivo hydrolysable amides thereof such as the primary amide, lower alkyl amides and di lower alkylamides thereof. Another class of pro drugs for the compound of the formula I consists of the analogous compounds of lower oxidation state, namely the corresponding compounds in which the CO2H groups is replaced by a CHO or CH2OH group. A particularly suitable class of pro drugs is that consisting of corresponding compounds wherein the co2H group is replaced by a group of one of the subformulae a CH2 CO CH3 a CH2 CHOH CH3 b CH C OR5 CH3 c CHOH CO CH3 d CHOH CHOH CH3 e CH2 C OR5 CH2 f CH2 C OCOR5 CH2 g CH C OCOR5 CH3 h CH2 C OR6 OR7 CH3 i CH2 CH OCOR8 CH3 j wherein is C1 4 alkyl R6 and R7 are each C1,4 alkyl or together are CH2CH2 94 CH2CH2CH2 1 and R8 is C 1 4 alkyl optionally substituted by phenyl or optionally salified amino R8 is preferably methyl. Particularly suitable C14 alkyl groups are methyl or ethyl. Particularly suitable pro drugs for the compound of the present invention include those containing a group of the sub formulae a , b , d or e as hereinbefore defined, that is, compounds of the formulae II , IIT , IV or V .EMI4.1 Certain preferred pro drugs are those containing a group of the sub formula a , that is, compounds of the formula II Apt pharmaceutically acceptable salts for the compounds of the formula I include alkali metal and alkaline earth metal salts, particularly the sodium, potassium, calcium and magnesium salts, and salts of pharmaceutically acceptable nitrogenous bases such as the ammonium salt and salts of protonated pharmaceutically acceptable amino acids,such as H3 N.CH2.COOH. In the compounds of the formula I and the pharmaceutically acceptable salts and pro drugs thereof R1 and R2 may be the same or different and may be hydrogen, halogen or C1 4 alkyl. When Rl or R2 is halogen it is usually chlorine or bromine. When R1 and R2 are halogen they will usually be the same. when one of R1 and R2 is hydrogen and the other is halogen, the halogen atom is often in the 4t position. When R1 and R2 ar both balogen, they are often in the 4 and 5 positions. When R1 or R2 is C1 4 alkyl, suitable examples thereof include methyl, ethyl and n and iso propyl, more suitably methyl. When Rb and R2 are both C104 alkyl they are usually the same. When one of R1 and R2 is hydrogen and the other isC104 alkyl, the alkyl group is often in the 5 position. when both R1 and R2 are C1 4 alkyl, they are often in the 3 and 5t positions or the 4 and 51 positions. In the compounds of the formula I , certain specific moieties of the formula EMI6.1 are 4 chloropyrroloyl, 4 bromopyrroloyl, 4,5dichloropyrroloyl, 4,5 dibromopyrroloyl, 5 methylpyrroloyl, 5 ethylpyrroloyl, 3,5 dimethylpyrroloyl, 3,5 diethylpyrroloyl, 4,5 dimethylpyrroloyl, 4,5diethylpyrroloyl. R1 and R2 will preferably both be hydrogen. R3 may be hydrogen or C14 alkyl. When R3 is C14 alkyl, suitably examples thereof include methyl, ethyl and n and iso propyl, more suitably methyl. R3 is preferably methyl. R4 is preferably hydrogen. nis preferably 0. From the foregoing it will be realised that certain particularly suitable compounds of invention are those of the formula VI EMI7.1 wherein the RI and E are as defined in formula I , pharmaceutically acceptable salts thereof and pro drugs thereof of the formulae VIII , IX , X , XI and XII EMI7.2 EMI8.1 wherein the variables are as defined in formula I . Suitable and preferred values of R1 and R2 are as described under formula I . A particularly suitable compound of this invention is therefore 2 carboxymethyl 1,4 dimethyl 5 l methy 21 pyrroloyl pyrrole 3 . A second group of compounds of the present invention of interest are those of the formula XIII EMI8.2 wherein R1 and R2 are as defined in formula I , pharmaceutically acceptable salts thereof and pro drugs thereof of the formulae XII , XIII , XIV and XV EMI9.1 A third group of compounds of the present invention of particular interest are those of the formula XVI EMI10.1 wherein R4 is as defined in formula I , pharmaceutically acceptable salts thereof and pro drugs thereof of the formulae XVII XVIII , XIX and XX EMI10.2 EMI11.1 wherein R4 is as defined in formula I It will be appreciated that compounds of the formula I wherein R4 is methyl and pharmaceutically acceptable salts and pro drugs thereof have an asymmetric centre.The present invention extends to the enantiomers thereof and the racemates of these enantiomers. The compounds of the present invention are most suitably provided in crystalline form. The present invention also provides a process for the preparation of a compound of the formula I or a pharmaceutically acceptable salt thereof, which process comprises the basic hydrolysis of a compound of the formula XXi EMI11.2 wherein Rl, R2, R3, R4 and n are as defined in formula I and L is CN or a group CO2R9 in which R9 is C14 alkyl and thereafter if desired converting R3when hydrogen in the resultant compound of the formula I to C1 6 alkyl and if desired acidifying the resulting salt to form a compound of formula I , or converting the salt to a pharmaceutically acceptable salt thereof, or to another pharmaceutically acceptable salt thereof. Conversion of h when hydrogen to an R3 C16 alkyl group may be carried out conventionally, for example by sequential reaction with an inorganic base and the relevant alkyl iodide in a polar inert solvent such as tetrahydrofaran. Suitable bases include sodium hydride. A preferred base is the combination of butyllithium and di isopropylamine. The hydrolysis may be effected using an hydroxide such as sodium hydroxide, in aqueous ethanol. The free acid of the formula I may be prepared by treating the resultant salt with hydrochloric acid the like. Pharmaceutically acceptable salts of the compounds of the formula I may be prepared by ion exchange. The present invention provides a further process for the preparation of a compound of the formula I wherein R3 is C1,6 alkyl or a pharmaceutically acceptable salt thereof, which process comprises decarboxylating a compound of the formula XXII EMI13.1 wherein R10 is C 1 4 alkyl when n O or hydrogen when n 1 and if desired salifying the resultant compound to give a pharmaceutically acceptable salt directly or converting a salt to a pharmaceutically acceptable salt. Decarboxylation may be carried out in conventional manner, for instance by heating a melt of the compound of the formula XXVII at moderately elevated temperature e.g. 180 220 C, under an inert atmosphere, such as nitrogen, until evolution of carbon dioxide has ceased. Subsequent optional process steps may be carried out as hereinbefore described. The following Scheme I shows synthetic pathways to compounds of the formula I Scheme 1EMI14.1 It is believed that compounds of the formulae XXI to XXVIII are also novel, and as such intermediates of the formulae XXI and XXIII fown an aspect of the present invention. Intermediates of the formula XXI wherein L CN may be prepared by treating a compound of the formula xyNlII with the complex formed between phosphorus oxychloride and the amide shown in Scheme 1. This reaction is generally carried out under the conditions conventionally used for Vilsmeyer reactions. Compounds of the formula XXVIII are prepared in analogy with known compounds Intermediates of the formula XXI wherein L CO2R9 as hereinbefore defined may be prepared by decarboxylation of a compound of the formula XXII see Scheme I , under conditions substantially as hereinbefore described for the decarboxylation of compounds of the formula XXIII . Compounds of the formula XXII are prepared by analogy with known compounds. Intermediates of the formula XXIII may be prepared by de esterifying a compound of the formula XXIV see Scheme I , under condition substantially as hereinbefore described for the de esterifioation of compounds of the formula XXI wherein L C02R9 as defined. Compounds of the formula XXIV may be prepared by analogy with known compounds. The present invention also provides a process for the preparation of a pro drug of a compound of the formula I which is an in vivo hydrolysable ester thereof, which process comprises esterifying the compound of the formula I or active acylating derivative thereof with the corresponding alcohol. Esterification of the acid itself may be carried out in conventional manner, for instance under acid catalysis and or under reflux in an inert solvent having a non extreme boiling point such as less than 1000C. Alternatively it may be carried out in the presence of a dehydrating agent such as dicyclohexylcarbodiimide. The present invention additionally provides processes for the preparation of a pro drug of a compound of the formula I which is an in vivo hydrolysable amide thereof, which process comprises reacting an active derivative of the compound of the formula I with ammonia or a corresponding amine. Suitable active acylating derivatives of the acid of the formula I for esterification and amidation include acid halides such as the acid chloride, the acid anhydride, mixed anhydrides such as those formed from ethyl chloroformate and esters such as the methyl and ethyl esters. The reactions are normally carried out in nonhydroxylic organic solvent such as tetrahydrofuran, ethyl acetate, toluene, dichloromethane and NN dimethylformamide. Esterification is normally carried out in the presence of an acid acceptor such as pyridine or triethylamine. The reactions may be carried out at any non extreme temperature such as 10 100 C and more suitably o 80 C, for amidation most suitably 10 50 C. The higher reaction temperatores are employed with less active derivatives of the acid of the formula I such as esters whereas the lower temperatures are employed with the more reactive derivatives of the acid of the formula I such as mixed anhydrides.. The present invention further provides a process for the preparation of a pro drug of a compound of the formula I in which the C02H group is replaced by aCHO group, which process comprises the reduction of an acid halide of the compound of the formula I . The reaction may be suitably carried out underRosenmung reduction conditions, that is with hydrogen using a palladium baxium sulphate catalyst in an inert organic solvent. A small amount of quinoline and sulphur may be added Suitable solvents include anhydrous acetone, ethyl acetate and xylene. The reaction may be carried out at a temperature in the range 10 to 150 C. Tri n butyl tin may also be used as a reductant. The present invention provides a process for the preparation of a pro drug of a compound of the formula 1 in which the CO2H group is replaced by a CH2OH group which process comprises the reduction of a compound of the formula I in which the CO2H group has been replaced by a CHO group. This reaction may be suitably carried out with a mild complex hydride such as sodium borohydride or a structurally hindered complex hydride such as lithium tri t butoxyaluminium hydride. Reaction is usually carried out in a solvent conventionally regarded as compatible with the reductant used at a non extreme temperature such as 30 to 800C, more suitably 10 to 600C, depending on the reductant employed. The present invention also provides a process for the preparation of a pro drug of a compound of the formula I wherein the CO2H group is replaced by a group of the sub formula a as hereinbefore defined, that is, a compound of the formula II as hereinbefore defined, which process comprises oxidising a compound of the formula XXIX EMI18.1 wherein the variables are as defined in formula I . The oxidation is suitably carried out in aqueous dimethylformamide solution in the presence of palladium chloride and cuprous chloride using pure oxygen or air.In general it is sufficient to blow air through the reaction mixture at an ambient or slightly elevated temperature to effect oxidation. The desired compound may be obtained from the reaction mixture by dilution with water followed by extraction into water immiscible solvent such as chloroform which may then be dried and evaporated. This initial crude material may be purified chromatographically if desired, for example by column chromatography over silica gel using 1 1 ether petrol as eluant. The compounds of the formula XXIX may be prepared by the decarboxylation of a corresponding compound of the formula XXX EMI19.1 wherein R1, R2, R3 R4 and n are as defined in relation to formula I . The decarboxylation may be effected by heating, for example to 170 2T00C. The desired product may be obtained by trituration under a non hydroxylic solvent such as chloroform. The acid of the formula XXX may be obtained by hydrolysis of the corresponding ethyl ester using normal sodium hydroxide solution followed by neutralisation with hydrochloric acid. The desired ethyl ester may be prepared by the alkylation of the corresponding compound of the formula XXXI EMI19.2 wherein R1, R2, R3, R4 and n are as defined in relation to formula I . Such alkylations may be brought about by generating an anion of the formula XXXI , for example with sodium hydride in dimethoxyethane, and quenching said anion with allyl bromide when n O or 4 bromobut l ene when n 1. The ethyl ester of a compound of the formula XXX wherein R4 is a methyl group may alternatively be prepared by methylation of the corresponding ethyl ester wherein R4 is a hydrogen atom, for example by sequential reaction with sodium hydride and methyl iodide. Alternatively, compounds of the formula XXX may be prepared by direct alkylation of a compound of formula I with, for example allyl bromide when n O in the presence of diisopropylamide. Compounds of the formula XXXI are novel and thus form an aspect of this invention as intermediates to pro drugs of compounds of the formula I of formula II . Another process of this invention suitable for preparation of a pro drug of a compound of the formula I wherein the CO2H group is replaced by a group of the subformula a as hereinbefore defined comprises the decarboxylation of compound of formula XXXII EMI20.1 wherein R1, R2, R3, R4 and n are as hereinbefore defined with relation to formula I . The decarboxylation may suitably be carried out by heating in an inert solvent such as DMSO. Compounds of the formula XXXII may be prepared by converting a compound of formula XXXIII EMI21.1 to an active derivative thereof such as that wherein theC02H group is replaced by C02COEt and then treating the active derivative with a mixture of bis trimethylsilyl malonate and butyllithium Synthesis 1979 p. 787 . Compounds of the formula XXXIII may be prepared as described for compounds of formula I or by analogous methods thereto. The present invention additionally provides a process for the preparation of a pro drug of a compound of the formula I wherein the C02H group is replaced by a group of the sub formula b as hereinbefore defined, that is, a compound of the formula III as hereinbefore defined, which process comprises the reduction of a corresponding compound of the formula liy as hereinbefore defined. Such a reduction may use a complex hydride such as sodium borohydride. Mild conditions and avoidance of excess reagent prevent reduction of the carbonyl adjacent to the pyrrole rings. The desired compound may be purified by conventional methods of column chromatography. The present invention further provides a process for the preparation of a pro drug of a compound of the formula I wherein the CO2H group is replaced by a group of the sub formula c as hereinbefore defined, that is a compound of the formula XXXIV EMI22.1 wherein R5 is as defined in sub formula c and the remaining variables are as defined in formula I which process comprises the enol etherification of a compound of formula I wherein the CO2H group is replaced by a group of sub formula a . This process is analogous to that described in Belgian Patent No. 866,857 USPatent No. 4200645 . The present invention also provides a process for the preparation of a pro drug of a compound of the formula I wherein the C02H group is replaced by a group of the sub formula d as hereinbefore defined, that is a compound of the formula IV as hereinbefore defined, which process comprises the oxidation of a compound of the formula XXXIV as hereinbefore defined. The oxidation is suitably carried out using mchloroperbenzoic acid at 0 5 C in mixed solvents such as diethyl ether water The present invention further provides a process for the preparation of a pro drug of a compound of the formula I wherein the CO2H group is replaced by a group of the sub formula e as hereinbefore defined that is a compound of the formula v ás hereinbefore defined, which process comprises the reduction of a corresponding compound of the formula bV as hereinbefore defined. Such a reduction may be effected using a complex hydride such as sodium borohydride under conditions which are conventional therefor. The present invention additionally provides processes for the preparation of pro drugs of compounds of the formula I wherein the CO2H group is replaced by a group of the sub formulae f , g , h , i or j as hereinbefore defined, that is, compounds of the formulae XXXV , XXXVI , XXXVII , XXXVIII or XXXIX EMI23.1 wherein R5, R6, R7 and R8 are as defined in subformulae a k and the remaining variables are as defined in formula I . These processes are as conventional, and are analogous to those described in Belgium Patent No. 866,857 US Patent No. 4200645 more specifically, enol acylation, enol etherification 5 and acetal formation may be carried out as described in US Patent No. 4180585 and acylation may be carried out as described in UK Patent No.1538473. Scheme IIEMI24.1 The enantiomers of compounds of the formula I wherein R4 is methyl and pharmaceutically acceptable salts and pro drugs thereof may be resolved from their racemates by conventional resolution techniques. In a further aspect this invention provides a pharmaceutical composition which comprises a compound of the formula I or a pharmaceutically acceptable salt or pro drug thereof, and a pharmaceutically acceptable carrier. The compositions of this invention are useful in treating rheumatic and arthritic conditions because of their anti inflammatory and analgesic properties. The compositions may be adapted for administration via the topical, oral, rectal or injection routes but it is preferred that they are adapted for oral administration. The compositions of this invention may contain diluents, binders, fillers, disintegrants, flavouring agents, colouring agents, lubricants, preservatives or the like in conventional manner. These conventional excipients may be employed in conventional manner, for example as in the preparation of compositions of keto profen, indomethacin, naproxen, acetylsalicylic acid or other anti inflammatory analgesic agents. Most suitably the composition of this invention will be in the form of a unit dose such as a tablet, capsule or reconstitutable powder in a sachet. Such unit doses will generally contain from 10 mg to 1000 mg and more suitably will contain from about 30 mg to 500 mg for example 50 mg to 250 mg of active agent, for example about 50, 100, 150, 200, 250, 300, 350, 400, 450 or 500 mg. These compositions may be administered once or more times a day, for example 2, 3 or 4 times daily, so that the total daily dose for a 70 kg adult will usually be in the range of 100 to 3000.mg and more usually in the range 300 to 3000 mg for example 500 to 2000 mg. Alternatively the unit dose may contain from 2 20 mg of active agent and may be administered in multiples if desired to give the preceeding daily dose. A favoured form of the composition of this invention is a hard gelatin capsule containing the active agent.The active agent may be in the form of a powder, granulate or the like and may advantageously be in intimate mixture with a lubricant such as magnesium stearate. A further favoured form of the composition of this invention is a tablet containing the active agent.The active agent may be in the form of a recompressed granulate of the active ingredient in intimate mixture with a lubricant such as magnesium stearate, a filler such as microcrystalline cellulose and a disintegrant such as sodium starch glycollate. This present invention also provides a method of treating inflammatory and or painful conditions in mammals which comprises administering per day from 50 to 4000 mg of a compound of this invention and more usuallly from 100 to 3000 mg for example from 200 to 1500 of a compound of this invention. Mammals which may be thus treated include humans and domestic animals such as dogs, cats or horses. Most suitably the medicament will be administered orally as 2, 3 or 4 doses per day at the dose level previously indicated. Description 1 2 Cyanomethyl 1 methyl 5 1 methyl 2 pyrroloyl pyrrole d.l EMI27.1 Oxalyl chloride 15 ml, 0.17 mole was added to l methylpyrrole 2 carboxylic acid 10 g, 0.08 mole in dry toluene 100 ml and the mixture refluxed for 21 2 hr.After allowing to cool the solvent was evaporated off and the residue dissolved in dry diethyl ether 100 ml before dropwise addition with cooling of dimethylamine 15 ml, 0.23 mole in dry diethyl ether. After completion of the addition the solution was stirred for 11 2 hr. and then the precipitated dinethylamine hydrochloride was filtered off and the filtrate evaporated to give the required dimethylamide The dimethylamide 12.16 g, 0.08 mole was treated with phosphoryl chloride 9.3 ml, 0.1 mole under nitrogen and the mixture stirred at 550C for 1 hr. 1 Methyl pyrrole 2 acetonitrile 18 g, O. 15 mole was added to the resulting complex and the mixture stirred for 61.2 hr. at 120 C. After cooling the resulting solid was dissolved in water 200 ml , basified with dilute aqueous sodium hydroxide and stirred for d hr. at 60 C. The mixture was again allowed to cool and after acidifying was extracted with chloroform 150 ml . The extracts were dried MgSO4 , the solvent removed under vacuum and the residue chromatographed silica gel 400 g eluted with ether to give the required product.N.m.r., 6 CCl4 4.78 3H, m 4.1 2H, m 3.96 3H, s 3.89 3H, s 3.69 2H, s . EXample 1 2 Carboxymethyl 1 methyl 5 1 methyl 2 pyrroloyl pyrrole 1 EMI29.1 The above acetonitrile d.l. 330 mg, 0.00145 mole was refluxed for 3 hr. in a solution of dilute aqueous sodium hydroxide methanol 50 ml . On cooling the solution was washed with diethyl ether 2 x 25 ml and the aqueous layer acidified with conc. HC1. The resulting precipitate was extracted into chloroform 2 x 50 ml and the organic layer separated, dried MgS04 and evaporated to dryness.The residue was decolourised with charcoal and recrystallised from diethyl ether to give the required acid.M.pt 155 157 CN.M.r., 6 CDCl3 10.00 1H, brs 6.80 3H, m 6.11 2H, m 3.93 3H, s 3,86 3H, s and 3.72 2H, s .Analysis Found C, 63.41 H, 5.77 N, 11.38 C13H14N2O3 requires C, 63.42 H, 5.69 N, 11.38. Description 2 4 l Methvl 2 pvrryl butane 2,4 dione d.2 EMI30.1 A solution of 2 acetyl l methylpyrrole 4.3 g, 0.36 mole in dry dimethoxyethane 250 ml was added dropwise to a cooled, stirred solution of sodium hydride 21.6 g of 80 dispersion in oil, 0.72 mole and ethyl acetate 70 ml, 0.72 mole in dimethoxyethane 150 ml under nitrogen. After the hydrogen evolution had ceased, the solution was heated under reflux four 21 2 hr. On cooling, the reaction mixture was treated with a few drops of water before being acified with aqueous 5N HC1. The brown oil which resulted was extracted into diethyl ether 2 x 150 ml and then washed with 10 aqueous NaOH 2 x 100 ml The combined aqueous washings were acidified with conc.HC1 solution and then extracted into diethyl ether 2 x 100 ml . The organic layer was washed with water 2 x 100 ml , dried Na2SO4 and concentrated to leave 4 1 methyl 2 pyrryl butene 2,4 dione as a brown oil 51.5 g, 87 . Description 3 3 Ethoxycarbonyl 2 ethoxycarbonylmethyl 4 methyl 5 l methyl 2 pyrroloyl pyrrole d. 3 EMI31.1 A solution of sodium nitrite 8.97 g, 0.13 mole in water 13 ml was added dropwise to a mixture of the above diketone d.2 20.8 g, 0.126 mole in glacial acetic acid 200 ml , the temperature being maintaiïned just below 8 C. After Completing the addition the mixture was stirred at the same temperature for a further hr. and allowed to come to room temperature over 2 hr. The resulting solution was then added dropwise to a solution of diethyl acetone 1,3 dicarboxylate 22.9 ml, 0.126 mole in glacial acetic acid 200 ml at 70 C.At the same time there was added portionwise a mixture of zinc 26.4 9 0e378 mole and sodium acetate 31 g, 0.378 mole , the temperature being kept below 900C. After complete addition, the mixture was ref fluxed for 1 hr. and then poured slowly into water 3 1 . The black oil produced was extracted into ethyl acetate, and the extract then washed with lOto aqueous NaOH and water before being dried Na2S04 and concentrated to leave a black oily solid 37 g .This material was filtered through a silica column 300 g using diethyl ether eluant and the solid obtained was recrystallised from toluene 60 800 petrol to afford the diester as a pink solid.M.pt 102 5 CN.m.r., 6 CCl4 11.27 1H, brs 6.8 6.4 2H, m 5.98 1H, m 4.16 2H, q, J 7Hz 5.06 2H, q, J 7Hz 3.87 5H, s 2.34 3H, s 1.29 3H, t, J 7Hz and 1.24 3H, t, J 7Hz . 3 Methoxycarbonyl 2 2 methoxycarbonylethyl 4 methyl 5 1 methyl 2 pyrroloyl pyrrole d.4 was prepared analogously using dimethyl 3 oxo adipate in place of diethyl acetone 1,3 dicarboxylate 24 yield, white solid .M.pt 109 110 CN.m.r., 6 CCl4 10.90 1H, br, s 6.90 6.35 2H, m 6.10 5.80 1H, m 3.83 3H, s 3.70 3H, s 3.57 3H, s 3.13 2H, d, J 7Hz 2.57 2H, d, J 7Hz and 2.30 3H, s . Descriotion 4 3 Ethoxycarbonyl 2 ethoxvcarbonylmethyl 1,4 dimethyl5 1 methyl 2 pyrroloyl pyrrole d. 5 EMI33.1 Anhydrous potassium carbonate 17.9 g, 0.13 mole followed by dimethyl sulphate 10.4 ml, 0.11 mole was added to a solution of the above diethyl ester d.3 18 g, 0.052 mole in ethyl methyl ketone 300 ml , and the mixture was refluxed for 16 hr. After cooling the solution was poured into water 400 ml , and the product extracted into diethyl ether 2 x 150 ml . The ether layers were washed with water 2 x 100 ml , dried Na2S04 and evaporated to dryness. The resulting solid was recrystallised from diethyl ether petrol to afford the diester as a pink solio.M.pt. 94 95 CN.m.r., ô CDCl3 6.85 1E, m 6,63 1H, m 6.10 1H, m 4.28 2H, q, 7Hz 4.18 2H, q, J 7Hz 4.10 2H, s 3.96 3H, s 3.56 3H, s 2.20 3H, s 1.33 3H, t, J 7Hz and 1.26 3H, t, J 7Hz . 3 Methoxycarbonyl 2 2 methoxycarbonylethyl 1,4 dimethyl 5 1 methyl 2 pyrroloyl pyrrole d.6 was prepared analogously from the diester d.4 . 91 yield, white solid .M.pt. 97 98 CN.m.r., 6 CDC13 6.95 6.75 1H, m 6.75 6.50 1H, m 6.27 6.02 1H, m 3.97 3H, s 3.78 3H, s 3.66 3H, s 3.57 3H, s 3.50 3.0 2H, m 2.90 2.40 2H, m and 2.17 3H, s . Description 5 3 Carboxy 2 carboxymethyl 1,4 dimethyl 5 1 methyl2 pyrroloyl pyrrole d.7 EMI35.1 The above N methylated diester d.5 12.93 g, 0.036 mole in ethanol 50 ml and 25 sodium hydroxide solution 200 ml were refluxed for 11 2 hr. After cooling the solution was poured into dilute hydrochloric acid 400 ml with cooling and stirring. The resulting white precipitate was filtered off, washed with water and dried to afford the required diacid.M.pt 236 240 C dec. N.m.r., CDCl3 d6 DMSO 6.97 1H, m 6.57 1H, m 6.08 1H, m 4.10 2H, s 3.94 3H, s 3.52 3H, s and 2.14 3H, s . 3 Carboxy 2 2 carboxyethyl 1,4 dimethyl 5 1 methyl 2 pyrroloyl pyrrole d.8 was prepared analogously from the diester d.6 98 yield, white solid .M.pt. 197 198 CN.m.r, 6 d6DMSO 11.93 2H, br, s 7.20 1H, t, J 2Hz 6.64 1H, dd, J 4 and 2Hz 6.14 1H, dd, J 4 and 2Hz 3.95 3H, s 3.60 3H, s 3.2 2.2 4H, m and 2.15 3H, s . Description 6 3 Carboxy 2 ethoxycarbonylmethyl 1.4 dimethyl 5 1 methyl2 pyrroloyl pyrrole d.9 EMI37.1 The above diacid d.7 3.5 g, 0.0115 mole was suspended in 0.5 ethanolic hydrochloric acid 45 ml and refluxed for ft 4 hr. by which time all the solid had dissolved. The precipitate which formed on cooling the solution was collected, washed with ethanol and dried to afford the ester as a white solid. N.m.r., CDCl3 6.87 1H, m 6.68 1H, m 6.10 1H, m 4.19 2H, q, J 7Hz 4.13 2H, s 3.57 3H,s 2.21 3H, s and 1.27 3H, t, 7Hz . Example 2 2 Ethoxycarbonylmethyl 1,4 dimethyl 5 1 methyl 2 pyrroloyl pyrrole d. 10 EMI38.1 The above monoester d.9 3.46 g, 0.0104 mole was heated under nitrogen to 210 C for 21 2 hr. After cooling the resulting brown oil was dissolved in chloroform 100 ml washed with water 50 ml , dilute aqueous sodium hydroxide 50 ml and finally water 2 x 50 ml . The organic layer was dried Na2S04 , and evaporated to dryness and the resulting oil purified by column chromatography using silica gel 60 g eluted with 1 1 ether petrol to give the required product.N.m.r., 6 CDC13 6.77 1H, m 6.61 1H, m 6.05 1H, m 5.85 1H, s 4.14 2H, q, J 7Hz 3.9 3H, s 3.58 5H, s 2.00 3H, s and 1.25 3H, t, J . 7Hz . Example 3 2 Carboxymethyl 1 4 dimethyl 5 1 methyl 2 pyrroloyl pyrrole 2 EMI39.1 2 EthOxyCarbonylmethyl 1,4 dimethyl 5 lwmethyl 2 pyr roloyl pyrrole 2 2.7 g, 0.0094 mole was refluxed in ethanol 25 ml and 25 aqueous sodium hydroxide 100 ml for 2 tr. After cooling the solution was acidified with concentrated hydrochloric acid and the cloudy precipitate extracted into chloroform 100 ml . The organic layer was washed with water, dried Na2SO4 and evaporated to dryness to give an orange oil which solidified after triturating with 60 80 petrol. The solid was recrystallised from ether chloroform with charcoal decolourisation to afford the acid as a pale yellow solid. M pt 1l9 1200C N. m. r., ô CDCl3 9.73 1H, brs 6.79 1H, m 6.63 1H, m 6.08 1H, m 5.88 1H, s 3.92 3H, s 3.63 and 3.60 5H, overlapping s and 2.00 3H, s . Example 4 2 2 Carboxyethyl 1,4 dimethyl 5 1 methyl 2 pyrroloyl pyrrole 4 EMI40.1 3 Carboxy 2 2 carboxyethyl 1,4 dimethyl 5 1 methyl 2 pyrroloyl pyrrole d.8 8.35 g, 0.0264 mole was heated at about 200 210 C under nitrogen for 11 8 hr.The residue solid was recrystallised twice from diethyl ether chloroform using decolourising charcoal ta afford the title compound as a white solid 6.31 0.87 .M.pt. 147 149 CN.m.r., 6 CDCl3 , 10.83 1H, s 6.77 1H, t, J 2Hz 6.60 1H, dd, J 4 and 2Hz 6.03 1H, dd, J 4 and 2Hz 5.73 1H, s , 3.90 3H, s 3.60 3H, s 3.0 2.6 4H, m and 1.97 3H, s .Analysis Calculated for C15H18N203 C, 65.69 H, 6.57 N, 10.22 . Found C, 65.50 H, 6.65 N, 10.03 . ESCRIPTION 7 1, 4 dimethyl 5 1 methyl 2 pyrroloyl 1 2 pyrryl but 1 eneEMI41.1 The acetic acid of Example 3 3.019, 0.0116 mole was taken up in dry THF 50m1 and added dropwise with cooling to a solution of di isopropylamine 3.4ml, 0.024 mole and butyllithium 14.5ml of 1.6M sol., 0.0232m. in dry THF 30 ml under nitrogen. The solution formed was then allowed to come to room temperature over 2 hours before allyl bromide 1m1, 0.0116 mole was added. The reaction mixture was left stirring at room. temperature for 2 hours. On cooling in an ice bath, water 20 ml was added to the solution and was then acidified with dil. HC1 acid.The product was then extracted into ether, washed with water, dried and evaporated down to leave a dark solid. The crude product 2.2 g was heated under nitrogen at about 2000C for 45 mins. The solid melted at about 120 C and decarboxylation was seen to occur almost immediately. On cooling, the solid remaining was taken up in chloroform, washed with water, dried and concentrated to leave a dark solid. The resulting solid was chromatographed on silica 1009 using 25 ether petrol as eluent to afford a pale yellow oil which crystallized on cooling. Recrystallisation from 40 80 petrol gave the title compound as a white solid 48 50 C .Analysis C16H21N2 Calc. Found C 69.77 69.95 H 6.98 7.29 N 10.85 10.88 Example 5 4 1 , 4 Dimcthyl 5 1 methyl 2 pyrroloyl 2 pyrryl butan 2 oneEMI43.1 2 2 Carboxyethyl 1,4 dimethyl 5 1 methyl 2t pyrroloyl pyrrole from Example 4 11.36 g, 0.041 mole was dissolved in dry tetrahydrofuran 100 ml together with dry triethylamine 5.8 ml, 0.041 mole at 200C under nitrogen. Ethyl chioroformate 4.0 ml, 0.41 mole was added dropwise and solution stirred at 200C for 1 hour before storing at the same temperature for 24 hours prior to use.The white precipitate was filtered off and the filtrate added at 00C to a solution prepared by the treatment of bis trimethylsilyl malonate 20.0 g, 0.091 mole in dry ether 150 ml under nitrogen at 650C with a solution of n butyllithium in hexane 46.7 ml, 1.95 M 0.091 mole . The resultino solution was stirred at 0 C for 15 miautes before quenching the reaction by addition of 5 aqueous sodium bicarbonate 200 ml . The aqueous layer was separated and the organic layer further extracted with sodium bicarbonate solution 2 x 100 ml before combining the aqueous layers and acidifying with dilute hydrochloric acid. The acidic solution was extracted with ethyl acetate 2 x 150 ml , the organic layers then combined, washed with water 2 x 100 ml and solvent evaporated off to leave a red oil. This was heated at 80 C in dimethyl sulphoxide 50 ml for 20 minutes until gas evolution ceased, The solution was poured into saturated aqueous sodium bicarbonate 200 ml and the resulting solution extracted with ether 2 x 150 ml . The organic layers were combined, washed with water 2 x 80 ml , dried anhydrous Na2SO4 and concentrated to give a pale yellow solid.This was purified by recrystallisation from 1 1 hexane ether to give the title product as a white, crystalline solid, m.p. 110 111 C, n.m.r. CDCl3 6.78 1H, t, J 2Hz , 6.60 1H, dd, J 4 and 2Hz , 6.08 1H, dd, J 4 and 2Hz , 5.68 1H, s , 3.91 3H, s , 3.60 3H, s , 2.80 4H, s , 2.17 3H, s and 1.97 3H, s . The title compound may also be prepared by oxidation of the butene d7 in aqueous dimethylformamide, with palladium chloride in the presence of air. Example 6 4 1 l,4 Oimethyl 5 1 methyl 2 pyrroloyl 2 pyrryl butan 2 olEMI45.1 The butanone of Example 5 2.0 g, 0.0074 mole was dissolved in ethanol 100 ml and stirred for 1 hour at room temperature with sodium borohydride 0.27 g, 0.0074 mole . After the addition of saturated ammonium chloride solution 30 ml the mixture was concentrated and the residue partitioned between ether 100 ml and water 100 ml . The ether layer was washed with water 2 x 30 ml dried anhydrous Na2SO and concentrated. The resulting solid was recrystallised from 1 1 petrol ether to yield the title compound as a white erystalline solid, m.p.78 79 C, n. m. r. CDCl3 6.70 1H, t, J 2Hz , 6.53 1H, dd, J 4 and 2Hz , 5.97 1H, dd, J 4 and 2Hz , 5.65 1H, s , 4.0 3.3 IH, m , 3.85 3H, s , 3.55 3H, s , 2.78 Ih, s , 2.7 2.4 2H, m , 1.95 3H, 2 , 1.9 1.6 2H, m and 1.18 3H, d, J 6Hz Example 7 2 Acetoxy 4 1 ,4 Dimethyl 5 1 methyl 2 pyrroloyl 2 DvrrYl butane EMI46.1 The butanol of Example 6 1.8 g, 0.0066 mole was dissolved in dry toluene 50 ml together with pyridine 3 ml and cooled in an ice bath. The solution was treated dropwise with acetyl chloride 1.5 ml, 0.02 mole and stirred at room temperature for 2 hours. The solution was poured into ice water 100 ml and then extracted. with ether 2 x 80 ml .The organic layer was washed with water, IM HC1, water again, dried anhydrous Na2S04 and concentrated. The crude product was. chromatographed on silica gel using ether as eluant and the resulting oil was crystallised from 2 1 60 800 petrol ether to give the title compound as a white, crystalline solid, m.p. 34 35 C, n.m.r. CDCl3 6.73 1H, t, J 2Hz , 6.57 lH, dd, J 4 and 2Hz , 6.02 1H, dd, J 4 and 2Hz , 5.68 1H, s , 4.92 lH, sextet, J 6Hz , 3.88 3H, s , 3.57 3H, s , 2.7 2.4 2H, m , 2.0 1.7 2H, m , 2.02 3H, s , 1.98 3H, s and 1.27 3H, d, J 6Hz . EXAMPLE 8 2 2 Ethoxycarbonylethyl 1 methyl 5 1 methyl 2 pyrroloyl pyrrole 8 EMI47.1 In a similar manner to that carried out inDescription 1, the title compound was prepared by the reaction of thz appropriate morpholinoamideand 2 2Ú ethoxycarbonylethyl 1 methyl pyrrole. EXAMPLE 9 4 2 Carboxyethyl 1 methyl 5 1 methyl 2 pyrroloyl pyrroleEMI48.1 In a similar manner to Example 8 the title acid was prepared from the corresponding ethyl ester 8 . EXAMPLE 10 4 1 Methyl 5 1 methyl 2 pyrroloyl 2 pyrryl butan 2 one 10 EMI49.1 In a similar manner to that carried out in Example 5, the title compound was prepared from the acid 9 mp 64 65 CAnalysis for C16H18N2O2 Calc. Found C 69.77 69.95 H 6.98 7.29 N 10.85 10.88 PHARMACOLOGICAL DATA 1. Analaesic activity a. Mouse writhinq test In a conventional phenylquinone induced mouse writhing test, compound 1, 3 and 4 were active at the following dose per os. inhibitionEMI50.1 tb Compound SEP 16 SEP mg kg tb SEP 1 SEP 90 tb SEP 3 SEP 100 tb SEP 4 SEP 60 tb The value for compound 3 was calculated in a separate test to be 2.8 mg kg po.2. Anti inflammatory activitv a. Carraceenin test In a conventional carageenin induced oedema test in the rat, the results were as follows Compound Dose mq kg Mean Oedema A inhibitionControl 145.3 10.3 1 20 117.7 6.6 19 Control 106.0 6.01 3 12.5 70.62 6.31 33 Compounds 5, 6 and 7 produced inhibitions which were significantly different from controlse b. Cotton Pellet test In a convention cotton pellet induced granuloma test, the results were as follows Compound Dose m kg Granuloma Wt. m inhibitionControl 48.1 1 10 37.6 22 Control 35.2 3 5 26.1 26 0.05 p 0.02 Significance as assessed by Students t 0.01 p 0.001 test Tonicity No toxic effects were observed in any of the above tests.